← Back to Search

Monoclonal Antibodies for Non-Hodgkin's Lymphoma

Phase 2 & 3

Waitlist Available

Research Sponsored by Gilead Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed B-cell non-Hodgkin's lymphoma (low, intermediate, or high grade categories) treated with chemotherapy and/or radiotherapy with evidence of minimal residual disease

Age 16 and over

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying monoclonal antibodies to see how well they work in detecting residual disease in patients who have been treated for non-Hodgkin's lymphoma.

Who is the study for?

This trial is for patients with B-cell non-Hodgkin's lymphoma who have already undergone treatment but still show minimal signs of the disease. They shouldn't be allergic to mouse proteins, have other cancers within the last 5 years (except certain skin or cervical/uterine cancers), be pregnant/nursing, or recently involved in trials with investigational therapies.Check my eligibility

What is being tested?

The study is testing if monoclonal antibodies can better detect leftover lymphoma after treatment. It's a Phase II/III trial, which means they're checking both how well it works and refining its safety and effectiveness.See study design

What are the potential side effects?

While not explicitly listed here, monoclonal antibody imaging could potentially cause allergic reactions due to mouse protein content, as well as general side effects like fatigue or mild discomfort at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have B-cell non-Hodgkin's lymphoma treated but still have some remaining disease.

Select...

I am 16 years old or older.

Select...

I am able to get out of my bed or chair and move around.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor

1,082 Previous Clinical Trials

842,781 Total Patients Enrolled

44 Trials studying Lymphoma

3,225 Patients Enrolled for Lymphoma

William A. Wegener, MD, PhDStudy ChairGilead Sciences

1 Previous Clinical Trials

100 Total Patients Enrolled

1 Trials studying Lymphoma

100 Patients Enrolled for Lymphoma

Media Library

Treatment Clinical Trial Eligibility Overview. Trial Name: NCT00003338 — Phase 2 & 3

Lymphoma Clinical Trial 2023: Treatment Highlights & Side Effects. Trial Name: NCT00003338 — Phase 2 & 3

Treatment 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003338 — Phase 2 & 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any restrictions for participants in this clinical trial?

"Lymphoma patients that meet the age criteria of 16 to 120 years old may be accepted into this clinical trial that is looking for 60 participants."

Answered by AI

Are currently enrolling individuals for this experiment?

"This particular trial is not recruiting patients at this time, as denoted on clinicaltrials.gov. This specific study was posted on March 1st, 1997 and was last updated on August 12th, 2021. There are 1782 other trials that are recruiting patients."

Answered by AI

Does this research involve seniors who are octogenarians or above?

"According to the inclusion criteria, patients that want to enroll in this trial must be aged 16 to 120. Out of the 315 clinical trials for patients under 18, this is one of 1619 trials for patients over 65."

Answered by AI

How many different hospitals are participating in this trial?

"4 study sites are currently recruiting patients for this clinical trial; Cuyahoga Falls, Los Angeles, Baltimore, and other locations. To lessen the strain of participation, patients are encouraged to enroll at the study site nearest to them."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

1997. "Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00003338.

All > Childhood Leukemia > Lymphoma